Results 41 to 50 of about 11,074 (164)

Comparison of actions of crizotinib or alectinib on firing rate.

, 2015
Category S: both crizotinib and alectinib had the same effect on the firing rate. Category O: the drugs had opposite effects on the firing rate. Category C: only the effect of crizotinib was significant.
Makoto Kaneda (168546), Toshiyuki Ishii (53332), Shunichiro Iwasawa (782964), Yuichi Takiguchi (395734), Akemi Maeda (782966), Ryota Kurimoto (782965)   +5 more
core   +1 more source

Comparative Drug Response Profiling in Neuroblastoma Cell Lines and Patient‐Derived Tumor Organoids

Pediatric Blood &Cancer, EarlyView.
ABSTRACT High‐risk neuroblastoma remains a leading cause of pediatric cancer mortality, and improved preclinical models are needed to guide therapeutic developments. We screened seven high‐risk neuroblastoma cell lines and three patient‐derived tumor organoids with 528 compounds alongside bone marrow controls, and compared them with external datasets ...
Krzysztof Wierbiłowicz, Se Whee Sammy Park, Aironas Los, Ernest Liu, Nona Struyf, Tom Erkers, Sören Lehmann, Jan J. Molenaar, Jakob Stenman, Olli Kallioniemi, Päivi Östling, Brinton Seashore‐Ludlow, Kasper Karlsson   +12 more
wiley   +1 more source

Influence of Food With Different Fat Concentrations on Alectinib Exposure:A Randomized Crossover Pharmacokinetic Trial

, 2023
Background: Alectinib is the keystone treatment in advanced anaplastic lymphoma kinase–positive (ALK1) non–small cell lung cancer (NSCLC). An exposure–response threshold of 435 ng/mL has recently been established, albeit 37% of patients do not reach this
Esther Oomen-de Hoop, Mathijssen, Ron H J; id_orcid, Dingemans, Anne-Marie C, Dumoulin, Daphne W, Mathijssen, Ron H J, Daan A.C. Lanser, Veerman, G D Marijn, Lanser, Daan A C, Oomen-de Hoop, Esther, de Leeuw, Simon P, Peter de Bruijn, Koolen, Stijn L W, Paats, Marthe S, Ron H.J. Mathijssen, G.D. Marijn Veerman, Oomen-de Hoop, Esther; id_orcid, Dingemans, Anne-Marie C; id_orcid, Marthe S. Paats, de Bruijn, Peter, Paats, Marthe S; id_orcid, Simon P. de Leeuw, Daphne W. Dumoulin, Anne-Marie C. Dingemans, Stijn L.W. Koolen   +23 more
core   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Avascular necrosis during alectinib treatment: Case report

, 1987
Non-small cell lung cancer is the most common cause of cancer-related death worldwide. The incidence of anaplastic lymphoma kinase constitutes 3%-5% of all non-small cell lung cancer patients.
Pınar Gürsoy, Gursoy, Pinar, Dokumacı, Tülin, Duman, Birsen   +3 more
core   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial

Thoracic Cancer, 2021
Background The efficacy of crizotinib treatment for recurring EML4‐ALK‐positive non‐small cell lung cancer (NSCLC) previously treated with alectinib is unclear.
Daijiro Harada, Hideko Isozaki, Toshiyuki Kozuki, Toshihide Yokoyama, Hiroshige Yoshioka, Akihiro Bessho, Shinobu Hosokawa, Ichiro Takata, Nagio Takigawa, Katsuyuki Hotta, Katsuyuki Kiura, Okayama Lung Cancer Study Group   +11 more
doaj   +1 more source

Two Uncomplicated Pregnancies on Alectinib in a Woman With Metastatic ALK-Rearranged NSCLC: A Case Report

JTO Clinical and Research Reports, 2022
Lung cancer incidence is increasing in pregnancy due in part to advanced maternal age. A subset of patients with NSCLC during pregnancy harbor an ALK gene rearrangement.
Chloe Weidenbaum, DO, Christopher G. Cann, MD, Sarah Osmundson, MD, MS, Wade T. Iams, MD, MSCI, Travis Osterman, DO, MS   +4 more
doaj   +1 more source

Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy

, 2017
Rearrangements in anaplastic lymphoma kinase (ALK) gene and echinoderm microtubule-associated protein-like 4 (EML4) gene were first described in a small portion of patients with non-small cell lung cancer (NSCLC) in 2007.
Liao, Bin-Chi;Lin, Chia-Chi;Shih, Jin-Yuan;Yang, James Chih-Hsin, 林家齊;楊志新;廖斌志;施金元   +1 more
core   +1 more source

Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC

JTO Clinical and Research Reports, 2022
Introduction: The Blood First Assay Screening Trial revealed the clinical applicability of blood-based next-generation sequencing to identify patients with ALK-positive NSCLC for alectinib treatment.
Johannes Noé, PhD, Walter Bordogna, PhD, Venice Archer, MD, Vlatka Smoljanovic, MD, Magalie Hilton, MSc, Ryan Woodhouse, BSc, Simonetta Mocci, MD, PhD, Shirish M. Gadgeel, MD   +7 more
doaj   +1 more source